Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,340.00
Bid: 12,360.00
Ask: 12,362.00
Change: -76.00 (-0.61%)
Spread: 2.00 (0.016%)
Open: 12,234.00
High: 12,370.00
Low: 12,164.00
Prev. Close: 12,416.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

G7 to donate 1 billion COVID-19 vaccine doses to poorer countries

Thu, 10th Jun 2021 22:30

By Kate Holton

CARBIS BAY, England, June 10 (Reuters) - British Prime
Minister Boris Johnson expects the Group of Seven to agree to
donate 1 billion COVID-19 vaccine doses to poorer countries
during its summit starting on Friday, and help innoculate the
world by the end of next year.

Just hours after U.S. President Joe Biden vowed to
supercharge the battle against the coronavirus with a donation
of 500 million Pfizer shots, Johnson said Britain would
give at least 100 million surplus vaccines to the poorest
nations.

Johnson has already called on G7 leaders to commit to
vaccinate the entire world by the end of 2022 and the group is
expected to pledge 1 billion doses during its three-day summit
in the English seaside resort of Carbis Bay.

Some campaign groups condemned the plan as a drop in the
ocean, with Oxfam estimating that nearly 4 billion people will
depend on COVAX for vaccines, the programme that distributes
COVID-19 shots to low and middle income countries.

"As a result of the success of the UK's vaccine programme we
are now in a position to share some of our surplus doses with
those who need them," Johnson will say on Friday, according to
excerpts of the announcement released by his office.

"In doing so we will take a massive step towards beating
this pandemic for good."

COVID-19 has killed around 3.9 million people and ripped
through the global economy, with infections reported in more
than 210 countries and territories since the first cases were
identified in China in December 2019.

While scientists have brought vaccines to market at
breakneck speeds - Britain has given a first dose to 77% of its
adult population and the United States 64% - they say the
pandemic will only end once all countries have been vaccinated.

With a global population nearing 8 billion and most people
needing two doses, if not booster shots to tackle variants as
well, campaigners said the commitments marked a start but world
leaders needed to go much further, and much faster.

"The G7's aim to provide 1 billion doses should be seen as
an absolute minimum, and the timeframe needs to speed up," said
Lis Wallace at anti-poverty campaign group ONE.

"We're in a race with this virus and the longer it's in the
lead the greater the risk of new, more dangerous variants
undermining global progress."

Of the 100 million British shots, 80 million will go to the
COVAX programme led by the World Health Organization (WHO) and
the rest will be shared bilaterally with countries in need.

Johnson echoed Biden in calling on his fellow leaders to
make similar pledges and for pharmaceutical companies to adopt
the Oxford-AstraZeneca model of providing vaccines at cost for
the duration of the pandemic.

Leaving poorer countries to deal with the pandemic alone
risks allowing the virus to further mutate and evade vaccines.
Charities have also said that logistical support will be needed
to help administer large numbers of vaccines in poorer
countries.

The British doses will be drawn from the stock it has
already procured for its domestic programme, and will come from
suppliers Oxford-AstraZeneca, Pfizer-BioNTech,
Janssen, Moderna and others.

(Reporting by Kate Holton; editing by Guy Faulconbridge and
Grant McCool)

More News
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.